Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fluence Energy Inc. Class A Common Stock (FLNC) vs Novo Nordisk A/S (NVO) Price & Performance

Fluence Energy Inc. Class A Common StockTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Fluence Energy Inc. Class A Common Stock vs Novo Nordisk A/S — how do they compare? Fluence Energy Inc. Class A Common Stock trades at $6.11 (market cap $969.93M), while Novo Nordisk A/S trades at $38.31 (market cap $169.08B). The key difference: Novo Nordisk A/S is far larger — about 174.3× Fluence Energy Inc. Class A Common Stock's market cap, and Novo Nordisk A/S pays a 4.72% dividend while Fluence Energy Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fluence Energy Inc. Class A Common Stock for 0 Days and Novo Nordisk A/S for 116 Days on average.

FLNCNVO
Market Cap
$969.93M$169.08B
Volume
7,001,6489,259,152
Sector
UtilitiesHealth
52-Week High
$32.23$63.98
52-Week Low
$6.21$35.29
Typical Hold Time
0 Days116 Days
Enterprise Value
$1.02B$183.28B
Dividend Yield
—4.72%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fluence Energy Inc. Class A Common Stock

No Aura AI signal available yet.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.

The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLNC
100% Buy0% Sell
Avg holding period · 0 Days
NVO
68% Buy32% Sell
Avg holding period · 116 Days

Top news

Latest headlines on both assets

About Fluence Energy Inc. Class A Common Stock

Fluence Energy Inc. designs and delivers energy storage products, operational services, and asset optimization software for renewable-energy and storage applications worldwide.

Read more on FLNC →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO →